Abstract: Pediatric rheumatic diseases are characterized by autoimmunity and tissue injury，and dysregulation of the cytokine network constitutes their core pathogenesis.Among relevant pathways，the IL-12/IL-23 pathway acts as a pivotal mediator in immune inflammatory responses by regulating the differentiation of Th1 and Th17 cells.This article systematically reviews clinical research evidence and indications of IL-12/IL-23 pathway inhibitors for pediatric disorders including psoriatic arthritis，enthesitis-related arthritis and inflammatory bowel disease.It focuses on medication initiation timing，dose tapering and discontinuation regimens，drug administration for special populations，and drug safety concerns. In addition，it prospects the developmental trends of precision medicine in this field，providing references for standardized clinical application of IL-12/IL-23 targeted therapies in pediatric rheumatic immune diseases.

Key words: pediatric rheumatic immune diseases, IL-12/IL-23, pathway, targeted therapy

摘要： 儿童风湿免疫性疾病以自身免疫和组织损伤为特征，细胞因子网络失调是其核心发病机制，其中白细胞介素（IL）-12/IL-23 通路通过调控Th1 和Th17 细胞分化在免疫炎症反应中发挥枢纽作用。该文系统梳理了IL-12/ IL-23 通路抑制剂在儿童银屑病关节炎、附着点炎相关关节炎及炎性肠病等疾病中的临床研究证据与适应证，重点讨论了药物启动时机、减停策略、特殊人群用药及安全性问题。展望该领域精准医疗的发展方向，为IL-12/IL-23 靶向治疗在儿童风湿免疫病中的规范应用提供参考。

关键词: font-family:", font-size:17px, background-color:#FFFFFF, ">儿童风湿免疫性疾病, IL-12/IL-23, 通路, 靶向治疗